Eltrombopag Olamine in Dengue Fever: Systematic Review of Clinical Trials and Beyond

Abstract

Introduction. Worldwide, millions suffer from dengue fever, a mosquito-borne virus that is severe. No particular antiviral drugs exist, making dengue management difficult. New therapies like Eltrombopag Olamine, originally developed for thrombocytopenia, have shown promise. This study examines Eltrombopag Olamine's dengue fever treatment potential using literature, experimental data, and clinical implications. Methodology. This systematic review examines the available literature on the use of Eltrombopag Olamine for the treatment of dengue fever. Thorough keyword searches throughout databases like PubMed and Cochrane, as well as hand-searching of reference lists, provide a large data set for analysis. Result. The small-molecule thrombopoietin receptor agonist eltrombopag olamine showed immunomodulatory properties that are important in the treatment of dengue fever. Studies on dengue patients show that it successfully increases platelet counts, suggesting it may be useful in treating thrombocytopenia. Phase III studies are now investigating its effect on platelet counts and fluid leakage in dengue patients, which might lead to new and improved treatments in the future. Conclusion. The study highlights Eltrombopag Olamine's dengue fever management potential. Its novel approach and favorable patient results, including shortened hospital stays and improved quality of life, provide promise for dengue fever treatment. Policymakers and healthcare providers must fund more research to fully uncover its therapeutic effects. Eltrombopag Olamine might transform dengue treatment, improving efficacy and quality of life for millions.